Demo Walkthrough: Tanezumab for Osteoarthritis

Welcome to the walkthrough of the *Osteoarthritis: Tanezumab* demo Nest (open in your original tab). In this walkthrough, we'll explain the core functionalities of Nested Knowledge through this Nest. We encourage you to work through the Nest as you follow the walkthrough. The Nest available to you is a copy of the original and may be freely modified, so roll up your sleeves and get your hands dirty!

This Nest is a copy of a previously-completed review presenting the evidence regarding the safety and efficacy of tanezumab at different dosage levels for the treatment of osteoarthritis.

Nest Home

Home: Osteoarthritis: Tan	lezumab						C		
Nest Home	(Show Table of	Contents)	Protocol	Description Materials		Comments			
OseMbesed						Next Your Nextions	All Montions)		
Literature Search 2/2 Other Searces Depilozte Review	About This Next is a co for the treatme	opy of a previously-complete nt of estecarthritis.	d review presenting the ovidence regar	ding the safety and efficacy of tanezuma	h at different dosage levels	Mohamed Abdelmegeed 20 gilievin Kalmes			
icreening (10/10)	In this nest, you practicing addin included studies if you have any	a can examine the search, scr ng and running searches, incl s. To follow a guided malk-th questions, view page-specif	rening, tagging, and extraction complet aling and excluding records, editing the rough of this domo, please visit our doc ic documentation using the '?' in the up	Kevin, based on the paragraph below (in the introduction ne shaft), do you think it may be worth it to do sub analysis for and below only?					
hady inspector lagging 15/17 andigues Study Tags	Review 1	Fitle: acy of taneoumab for treatm	ent of chronic pain in patients with ost	exarthritis of the hip or knee: A report fro	en a living systematic	Also it seems that analysis of rapidly progress esteonecrosis are the most 2 important side of	ive OA (PROA) and Rects.		
huly inspector						0r			
Atraction 16/12	Authors								
hady inspector		Author Name	Author Role	Author Athilation		We just indude all deses combined?			
ynthesis		Nicale Hardy	Did 50% of the rest overall. Did ROB adjudication. General project	NK					
lenserpt follow sport			nanagement, Edits to manuscript. Senior authoristudy coordinator			Tanezamab, menodonal NGF antibodies, has completed pix clinical trials. (PMID: 3/065100; 3/2234) and is expected to the treatment of chronic pain in patients with OA or chroni			
dania	-	Mohamed Abdelmegeed	Wrote the manuscript First authoricorresponding author	54E		to include table tools, JUS notice that a to treatment related registing progression OA ([PMID: 25527216], and that Tanezumab combi- appeared to increase the risk of RPDA, relating membranes, IMMP: SEESERD, a relating	PROA) and osteomeoresis, ned with NSAIDs treatment e to Tanezumab initial built by the EDA to		
		John Pederson	Performed meta-analysis	SME/NK		assess the results of previous trials, and it was	s determined that there was		
			Second author			a dose-response relationship between osteor (dose range, 2.5-10 mg [PMID: 265548; 2817	ecrosis and Taneoursab 9540; 31207169), The		
		Kevin Kallmes	Provided general guidance on project.	NK		Provide a final district which is the final of the first	om 10 mg to Sing after		
		Bernadette Kane	Did 25% of nest.	NK			9 Q		
		Auad Rohmatullah	Did 25% of next and tables	NE					
		Kathryn Cowie	Did some tables	NK.					
		Kristen Hutzhison	Did RDB	NK					

You've landed on your demo Nest in AutoLit, and you're looking at the Nest Home page. This page includes a menu on the left of the page, the protocol in the center, and discussion about the Nest on the right. The menu includes links to all modules & configurations available to you in AutoLit. We'll now walk through these modules one by one. (click the title in the menu to navigate to the the corresponding module).

Literature Search

The Literature Search page allows import of studies to a nest and shows where studies were sourced. This review includes two searches - an API-based (automatic integration) search of PubMed and a filebased import from Embase. Hover and click the "History and Details" column to see greater detail about the searches, including when they were run and any query structuring available. The PubMed search is API-based and may be run on demand. Hover the Pubmed row and click the "Run" button to update this search- you may import some new records!

(NESTED) knowledge				0.	r Team Our Vision Enterprise AutoL	t Karl 🕥
E Literature Search: Osteoarthri	itis: Tanezumab				2/1	0
Nest Home	(Add Search)		Searches			(Interaction (B)
Dashboard	Term	Search Engine	Schedule	Search New	History and Details	Delete
Literature Search 202	tanezumab AND (osteoarthritis OR arthritis DR GA) AND pain	Other	Never	Last Run: 2022-01-17	Method: file Results: 95	
Duplicate Review Search Exploration Query Builder	tanesumab AND (ostesorthritis OR arthritis OR OA) AND ("randomized"	PubMed	(Never v)	(© Run) File 🛓	Fall History	
Screening III.JTT Configure Exclusion Resears Study Inspector						
Tagging 56/17 Configure Study Tage Study Imperior						
Extraction 5677						
Synthesis Mensoript biller Export						
Settings Admin						

Other Sources

Records may be imported through other means. Click the "Other Sources" menu item under "Literature Search" to view records that were individually added as expert recommendations. 19 such studies were imported into this Nest. Try importing the DOI or PMID of your favorite study using the "Add by Identifier" form on the right of the page.

Other Sources: Osteoarth	itis: Tanezumab					(
Nest Home		Add Individual Refer	ences Bibliomine			Add by Identifier	
lashboard	Title	Author	Source	Date Added	Added By	Add by Article ID	
Iterature Search 2/2	Based on minimal clinically important difference values, a moderat.	Di Zhao	Therapeutic Advances in Muscul	108/2022	Jade Thumham	× (PulMed ID (DOI	
her Sources plicate Review	Efficacy and safety of taneoumab monatherapy or combined with	Thomas J Schnitzer	Ann Rheum Dis	8/13/2021	Nicale Hardy	Enter a single or comma separated list of identifiers. I be automatically imported from Published or CrossRef	iibliographic data
arch Exploration arry Builder	Efficacy and safety of tanezumab monotherapy or combined with	Thomas J Schnitzer	Ann Rheam Dis	8/13/2021	Nicole Hardy	× Add Manually	
creening m/m	Safety and efficacy of suboutaneous tanezumab in patients with is	Charles Birbara	J Pain Res	8/13/2021	Nicole Hardy	× THE	
anfigure Exclusion Reasons hally Inspector	Safety and efficacy of subsubareous bareaumab in patients with $k_{\rm c}$	Charles Birbara	J Pain Res	8/13/2021	Nicole Hardy	Titk Author Format	
agging (16/10	Efficacy and safety of intravenous tanezumab for the symptomatic.	Exan Elman	The Journal of Rheumatology	8(10)/2021	Nicole Hardy	Pist/Lat M	
anfigure Study Tage tade Inspector	Efficacy and safety of intravenous tanezumab for the symptomatic	Exan F Ekman] Rheumatol	8/90/2021	Nicole Hardy	(Fint Last	
densking (2010)	Tanezumab reduces osteoarthritic knee pain: results of a randomiz	Mark Brown	JPain	6/15/2021	Bernadette Kane	Publication Date (mm / dd / yyyy	
tudy inspector	Nerve Growth Factor and Pain Mechanisms	Franziska Denk	Anna Rev Nearosci	6/15/2021	Bernadette Kane	X Publisher	
ynthesis	Anti-nerve-prowth factor in pain management: current evidence	David Chang	J Pain Res	6/15/2021	Bernadette Kane	Volume Volume Volume	
tanuacrigit Editor sport	Efficacy and Safety of Tanczumab on Distocentivitis Nexe and Hip $_$	Junyuan Chen	Pain Medicine	6/15/2021	Bernadette Kane	X Comparate Author	
ettinos	A systematic review of the efficacy and general safety of antibodie.	T.J. Schnitzer	Osteoarthritis and Cartiloge	6/15/2021	Bernadette Kane	K Una	
idenie	Current status of nerve growth factor antibodies for the treatment.	Rachel E Miller	Clin Exp Rhoumatol	6/12/2021	Asad Rahmatullah	(X) 500 (10000000000	
	Nerve growth factor antibody for the treatment of estapartfinitis p	Martin Schmelz	Pain	6/12/2021	Asad Rahmatullah	Abroat / Sumary Planholder	
	Targeting nerve growth factor, a new option for treatment of oste	Zigin Cao	Aging (Albany NY)	6/7/2021	Asad Rahmatullah	×	
	Pooled analysis of tanezumab efficacy and safety with subgroup a	Leslie Tive	J Pain Res	6/7/2021	Asad Rahmatullah		Callad
	Difficacy and safety of tanezumab administered as a fixed doxing re	Zheng-Rui Fan	Clin Rheamatol	6(9)/0021	Anad Rahmatullah		C Had Holes
	Efficacy and Safety of Taneoursab on Dateourthritis News and Hip	Junyuan Chen	Pain Med	694/2021	Asiad Rahmatullah	×	
	Tanezumab for Patients with Ostesarthritis of the Kneer & Mata-A	Shun-Li Kan	PLoS One	664/2025	Asad	(X)	

Screening

Once studies are imported into a nest, they are "Screened" for relevance to the review in the Screening Module. Click the Screening menu header to visit this module.

Screening: Osteoarthritis: Tar	nezumab			10/11		0
Vest Home without Jiteriture Search 212 Xiteritures Addute Indone and Defando	Generation of a high-fidelity antibody against nerve growth factor ur mutagenesis and validation with structures of the initial and optimize Li Peor.2014 Nerve growth factor (NGP) is indepenable during normal embryoric development ar promet factor (NGP) is indepenable during normal embryoric development correct a hydrodron-device (NGP-sayed) ensure antibody into a chiral consider. antbody lancomstb. a dist-i-class and hydrographic growth for an NGP-space.	sing library scanning ed Fab-antigen complexes. In critical for the amplification of pain signals in adults. Intervention in NGP signals is, cancer and chronic lower back disorders. We developed a fast, high-fidelity melt This method, termel lubrary scanning Mutageneration (JSM), resulted in the WLT-ability inclusion and structural comparisons between tomenandle and the nouse SII preva- tion of and structural comparisons between tomenandle and the nouse SII preva- tion of the NLT-ability network on the NLT-ability networks in the Intervent NLT between tomenandle and the nouse SII preva- tion of the NLT-ability network of the NLT-ability networks of the NLT-ability networks in the NLT-ability networks of the NLT	g holds red to h affinity sor		lavigation Screening	^ (B) ^ (4)
Screening 100/11	results suggest the potential for wide applicability of the LSM method for optimizable Population/Problem Intervention Outcome User Keyword	a de well-characterized antibodies during humanization.		Ex Train Inclusion Model	Esion Reason	(beladit
	(Keywords 💙	Elbliographic fields v	(Edt)	Tan	Tagging	0
Tagging (16(17))					Select Tap	0
Extraction (56/17) Rody Impector Synthesis Removiet Differ				Enter Tex		A Andy Teg
oport				≓ Cr	mments (0)	~
Settings				#	History	~

This screening module displays studies that have yet to be screened, allowing you to decide to include or exclude from the rest of your review and analysis. So far in our review, 110 studies have been screened and 17 included. Try including the last remaining reference by clicking the include button. You may exclude references by selecting an exclusion reason from the drop-down menu and then clicking the exclude button. You may also skip studies you aren't yet sure about, or jump to a prior study, using the buttons under the Navigation menu.

Abstract Highlighting

Why are study abstracts so colorful? We peform ML-based PICO annotation of abstracts using a model derived from RobotReviewer. To turn off PICO highlighting, toggle off the slide button in the legend just beneath the abstract text.

Abstract text may also be underlined with User Keywords, which are configured under the Settings menu item.

Tagging

The Tagging module allows included studies to be categorized according to their characteristics, such as design, population, outcomes, etc. Nested Knowledge uses hierarchical tags to describe characteristics.

Tag Hierarchy

Click the "Configure Study Tags" menu item to get started. Tag hierarchies consist of tags (visualized as points) and relationships between them (visualized as connecting lines). The tag hierarchy in this review includes 5 "root" tags - the highest level categories we're considering in the review. Hierarchies should be created and read as a series of "is a" relationships. For example, "Safety Event" is a "Outcome", "Abnormal Peripheral Sensations" is a "Adverse Event". Hover around the hierarchy to explore tags and read off the "is a" relationships a you go.



Tagging Module

Inside the Tagging module, tags may be applied to studies, indicating that a concept is relevant to a study.

5/10



In the Tagging form, select any tag from the dropdown menu, then click Apply Tag; it should now appear in the Tagging Table.

Click a row in the Tagging table that has a non-empty excerpt column to view past applied tags and their "excerpts", which user-entered pieces of text, typically extracted from the manuscript, supporting the tag.

Study Inspector

Study Inspector is the tool in AutoLit for reviewing and searching your past extracted data. Each row in Study Inspector is a study, and columns may be user-selected in the upper left dropdown menu. Studies may be searched into the table by creating Filters. Filters may be created using the Add Filter dropdown menu, but oftentimes the typeahead search bar is fastest. In the below example, we are filtering to studies with a full text uploaded and using the typeahead menu to find all included studies. Try out the title/abstract (TIAB) filter by typing "monotherapy" into the search bar.

Last update: 2023/06/27 21:52 wiki:start:demo:osteoarthritis https://wiki.nested-knowledge.com/doku.php?id=wiki:start:demo:osteoarthritis

Study Inspector: Ostecart	hritis: Tanezumab		C	16.17
Nest Home	Column v	Study Inspector		(Save V) (Filter Sets V) (Bulk Actions B) (Download &
Sephored	Add Filter (Lipkoded X) in			(Gear Filters
Jiterature Search 202	Title 1 Filter to included	to the Design from the	Publication Year 15	Screening Status
Wher Sources Sudicate Review	Anti-nerve growth factor in pain management: carret Filter to excluded by	In vitro (lab) study	2016	Excluded: Not a randomized controlled trial
icarch Exploration Joarn Duilder	Long-term open-label study of tanezumab for modes		2011	Excluded: Not a randomized controlled trial
	Efficacy and safety of intra-articular injection of trops Filter to Tagged Wit	h Interventions	2019	Excluded: Not on Tanazamab
Screening (A fully caninised anti-NCF monoclonal antibody for paterneous	th Index joint	2018	Excluded: In vivo (animal) study
Rody Importor	Imaging atlas for eligibility and on-study safety of potential sh	Roemer, FW	2015	Excluded: Not a tandomized controlled trial
Tagging (16/17	Safety, tolerability, pharmacolimetics, and efficacy of AMG 403.	Gew.IM	2015	Excluded: Not on Tanezamab
Configure Study Tage Rock: Incomplex	Imaging atlas for eligibility and on-study safety of potential kn	Roemer, FW	2015	Excludied: Not a tandomized controlled trial
	Tanezumab reduces esteoarthritic hip pairs results of a rando	Brown, Mark T	2018	Induded
Extraction ()	Haman onteopyte expression of Nerve Growth Factor: The eff	Stapledon, QM	2019	Excluded: Not a tandomized controlled trial
	Subcutaneous tanezumab for esteoarthyitis of the hip or leves	Berenbaum, Francis	2020	Induded
Synthesis Research Editor	TGF-beta is a potent inducer of Nerve Growth Factor in articul	Davidson, ENE	2015	Excluded: Editorial or opinion article
laport	Tanezumab reduces estacoarthritic levee pairs results of a rande	Brown, Mark Y	2012	Excluded: Duplicate
Settings	Responsiveness of Single versus Composite Measures of Pain L.	Parkes, Matthew	2018	Excluded: Not a tandomized controlled trial
ldmin	Efficacy and safety of tanezzmab added on to didofenac susta	Balanescu, Andra Rodica	2014	Included
	First-in-human condomized clinical trials of the safety and effic	Vitalicke, Patricia A	2018	induded
	Onset and maintanance of efficacy of suboutaneous tanezuma	Schwitzer, Thomas J	2020	Excluded: Secondary analysis
	Fulranumab in patients with interstitial cystitis/bladder pain sy	Wang, H	2010	Excluded: Not DA.
	Efficacy and safety of fasimumab in patients with chronic low	Dakin, P	2021	Excluded: Not DA.
	A systematic review of the efficacy and general safety of antib	Schnitzer, T J	20/5	Excluded: Not a condumized controlled trial
	Efficacy and safety of intravenous taxesumab for the sympto	Eleman, Exam	2014	Included
	Serious jaint-related adverse events in condumized controlled t	Hochberg, M.C.	20/5	Excluded: Not a condumized controlled trial
	Nerve prowth factor inhibition with tanezumab influences wel	Lathranche, TP	2017	Excluded: In vivo (animal) study
	Madel-based evaluation of cost-effectiveness of nerve growth	Losina, E	2016	Excluded: Not a randomized controlled trial
	Psychologies that related tansars much as a neural treatment for the r	Baarson Candana	2026	Parisdari Net Da

Extraction

Please see our Extraction Documentation page to review how Extraction was configured for this Nest. Click the Extraction menu item to view and perform Extraction for this review.

NESTED} NOWLEDGE					Our Team	Our Vision E	interprise	AutoLit	(Karl	1
Data Extraction: Osteoarthritis: T	anezumab						16,117			0
Nest Home To	anezumab reduces osteoarthritic hip pain:	stort FullText Supplements PubMed 🔍	72		Na	vigation				^
Deskbeard	acebo-controlled phase III trial.		(Bob)					(SHO	Complet	D
Literature Search 2/2	D Q ^ ↓ 1 etto -	+ 80% • R >>	2		Stu	dy Design				~
Other Sources Duplicate Review			Arms							
Search Exploration	ARTERITE & REPUTERTEM		Stetus		Intervention			Arm Skee	P	1
Query Builder	Vol. 66, No. 7, July 2013, pp 1793-1803 DOI 10.002/art.07900		1		10mg (SC)		~		10 8	
	@ 203, American College of Elevanoidage				Sme		~		15A P	
Screening ()					2.5mm		~		100 1	
Configure Exclusion Reasons					Discolo					
Ibady Inspector			-		Psacera		+		00 -	+
Tagging (1679)	Tanezumab Reduces	Osteoarthritic Hip Pain	Measurement	Points						
Configure Study Tace	1000000000 10000000	obteon uniter sup s un	Status	Timepei	with the second s	Value		Units	8	
Study Inspector			×	Baselin			0	days	8	
	Results of a Randomized, Double-Bli	nd, Placebo-Controlled Phase III Trial	×	Gubbern	e		72	days	ж	
Extraction 16/17										
that insertor	Mark T. Berson ¹ Frederick T. Murshy ² David M. Radin ³ Isobelle Davianon ¹			Extracted Data						
	Michael D. Smith.1 a	nd Christine R. West1	Ether Data Ear	autority.						5
Synthesis			Crimin band Car	internal Conservations				(Terr)		=
Manuscript Editor	Objective. To compare the efficacy of tanezomah	greups vereas 40% for placebo. Safety findings were	Abnormal Per	pheral Sensation	59			(1501	Children I	
Ispart	versus placebo for reducing pain and improving physi- cal function in patients with extense their (ChA) of the	similar to these previously reported. The tanccumab OA	Statas	Arm	Periphenal r	europethy	Hypoesthesia	PI	arseythesia	
	hip.	cause of AEs leading to joint replacement. Total joint		tong (KL		3		3		-
Settings	Methods. This was a 32-week, randomized,	replacements were reported in 8 patientic 1 in the 10 mg.	~	Sed		0		2		-
Landa .	deuble-blind, placebo-centrolled, phase III trial. Pa- tients with bouches Western Outsrie and McMueter	2 in the 5 mg, 2 in the 2.5 mg, and 3 in the placebo	~	2.5mg		2				-
	Universities O.S. Index (WOMAC) Pain and Physical	group, A total of 9 points were repraced (8 taps (7 index initial and 1 shoulder).	~	Placeba		0		,		_
	Function subscule scores of m5 and m4, respectively,	Conclusion. Our findings indicate that tan-	Age (Mean) <					10000	Cuttors	Ð.
	and patient's global assessment of OA as "fair," "poor,"	examab provides superior pain relief and improvement	Status	Arm	Heam	Range Lewer	Range	Upper	N	
	the Construction of the Co	in physical function and patient's global assessment	1	10mg (10)	63.3		B	79		197
	baseline to week 36 in WOMAC Pain and Physical	generally well tolerated.	1	Sing	61.8		28	88		194
	Function subscales and patient's global assessment,			2.5mg	62.5		26	80		155
	analyzed using analysis of covariance. Adverse events (AEx) were monitored throughout.	Approximately 12% of adults in the US develop	1	Pheebo	8.9		18	80		16
	Reads. Patients (n = 621) were randomized	occurring in 3-6% of whites and <1% of East Indians.	Any Adverse	Events Ø					outcome	
	1:1:1:1 to treatment with intravenous tancenmab 3.5 mg.	African Americans, Hong Kong Chinese, and Native	18afus		Lene .	Events		Te	esal.	
	5 mg, or 10 mg or placebo. Each tanerumab group	Americans (2). Current treatment options for painful	1	100	19 (SC)		89			12
	end points versus placeho (P = 0.001 for all). All	UN of the tap are largery madequate. Nonsterroutal antiinflammatory drugs and opioid analaesics are com-	1	1	ing		84			tiA
	incidence ranged from 59% to 58% across tanezomah	monly used (3). However, these medications have pro-	4	1	Simp		90			155
		tean gastrointestinal and cardiorenal side effects (4,5)	4	R	asba		60			155
	Clinical Trials gen identifier NCT00744473. Suspended by Plane, Inc.	and, for some patients, result in an unsatisfactory ther- specific sequence. Potent analysis: medications that are	Female 0					Cite	a Outors	Ð.
	Mark T. Brewn, MD, Isabelle Davignon, PhD, Midnael D.	well talerated may help to avoid or delay surgical	Status		Arm .	Events		T	cal.	-
	Steam, 1945, Christine P., Welf, PhD: Phase Inc., Decision, Connecticul, "Frenderick T. Marping, IDO: Allocena Contex for Clinical Research.	intervention (6).	1	10	0.6Cl					- 10
	Dunanterilli, Primitybunja, and Univariity of Primitybunja School of Medicine, Philadelphia: 'Oreid M. Badin, MD: Stamlard Therapea-	Nerve growth factor (NGP) is a neurotrophia that resultion the structure and function of NDE	1		ing					154
	tics Consortium, Mamberl, Connecticut, Des Roman, Davienum, Smith, and West and west of the	responsive sensory neurons, including small-diameter	1	1	Smo		101			
	certains in Pilter for the Marshe has account consulting for antity	revelopming afferent rathways claring fetal development.								-

The Study Design form specifies intervention arms in the study (placebo and 3 differing Tanezumab dosages, in this case) as well as outcome measurement timepoints in the study (0 and 112 days).

The Extracted Data form contains means, medians, dichotomous rates, and categorical counts corresponding to baseline characteristics and outcomes for the study. Modify some of the data points, which will be auto-saved. If you enter incomplete or invalid data (e.g. a negative value for N), the leading Status column of the table will show a red X. Hover to view the error message.

Synthesis

At this point, we've reviewed all the evidence gathered in AutoLit for the *Osteoarthritis: Tanezumab* Nest. Now let's navigate to Synthesis Home to draw some conclusions from our evidence, by clicking the Synthesis menu heading.

Contributors		Osteoarthritis: Tanezumab		AutoLit			
Sari Hako	This systematic review tanezumab for osteos baseline and follow-u change-tiene-baselin -0.2 (-2.3, -2.0) for con placebort/SAID. For a thwany, SJ.6% for tan related AEs were obs serious AEs were obs	This systematic review and meta-analysis presents 13 randomized controlled trials that analyzed pain and safety outcomes for patients treated with target pain and safety outcomes for patients treated with the safety and follow-up and adverse events (HeS), inducing transment-instable and serious AEs, were reported at follow-up and adverse events (HeS), inducing transment-instable and serious AEs, were reported at follow-up and adverse events (HeS), inducing transment-instable and serious AEs, were reported at follow-up and adverse events (HeS), inducing transment-instable and serious AEs, were reported at follow-up and adverse events (HeS), inducing transment-instable and serious AEs, were reported at follow-up and adverse events (HeS), inducing transment-instable and serious AEs, were reported at follow-up and adverse events (HeS), inducing transment-instable and serious AEs, were reported at follow-up and adverse events (HeS), inducing transment-instable and serious AEs, adverse events (HeS). For safety outcomes, AEs were events (HeS), for adverse adverse adverse events (HeS), inducing transments, instable adverse events (HeS), inducing transments, adverse events (HeS). For safety outcomes, AEs were eventsed at inducing (33.W for compations, G). The were event and in (HTM), ITM, ISM, ISM, ISM, ALSM, and JAPA for placebe transmitting. New eventserved in all transments, appendix the encoderse at the encoderse, adverse, and the encoderse, adverse,					
		Qualitative Synthesis	м	Most Frequent Tags			
		Browse common concepts discussed in studies of interest. You can interact with the tag diagram to	Tag	Frequency			
		tina studies that adaress your research goals.	Double-Blind	18			
			Abnormal Peripheral Sensations	10			
			Serieus Adverse Events	18			
	-•		Any Adverse Events	10			
				-			
		Quantitative Synthesis Examine summary data and statistical analysis. You can compare therapies across outcomes of interest or review evidence from the underlying studies.		Meta-Analysis			
			Outcomes	Interventions			
	$\cdot \setminus \cdot$		Abnormal Peripheral Sensations	Placebo			
	: X.		Serieus Adverse Events	Sing			
			Any Adverse Events	10mg (SC)			
			LS means PGA-OA	2.5mg			
PERMA Ta	X	Manuscript Read the authors' report of key findings and conclusions. You can also view updated methods, figures, and sources for this review.					

PRISMA

Click the PRISMA button in the bottom left of the page to view a PRISMA 2020 flow diagram. The diagram is auto-populated based on searches imported and studies screened in AutoLit.

Last update: 2023/06/27 21:52 wiki:start:demo:osteoarthritis https://wiki.nested-knowledge.com/doku.php?id=wiki:start:demo:osteoarthritis



We can see that the 2 searches and 9 (19 - 10 duplicated records already imported in search) expert recommendations are displayed in the diagram. The diagram may be right clicked and saved as an arbtirary resolution SVG or exported in a variety of formats.

Qualitative Synthesis

Navigate back to Synthesis Home and click the Qualitative Synthesis box. Qualitative Synthesis (QLS) displays data gathered in the Tagging Module. Each slice in the sunburst diagram is a tag. Its width corresponds to how frequently it was applied. Its distance from the center corresponds to its depth in the hierearchy (how many "is a" relationships are between it and its root tag). Click a slice to filter studies displayed to those where the tag was applied. Clicking multiple slices filters to studies with all the selected tags applied. The rightmost bar shows relevant studies (bottom) and some data about the tag (top), like its frequency, excerpts, and tags that were commonly applied with the selected tag.



In this tag selection, we see that some Serious Adverse Event was reported as an outcome in 12 studies that included a 5mg dose as an intervention. Click the rows of the study table to take a deep dive into the extracted data.

Quantitative Synthesis

Navigate back to Synthesis Home and click the Quantitative Synthesis box. Quantitative Synthesis (QNS) displays data gathered in the Extraction Module. QNS contains 3 different analyses automatically computed from extracted data.

The Summary tab contains pooled estimates of outcomes, broken out by interventions. Interventions may be expanded to different levels of precision, while outcomes analyzed may be selected from the dropdown menus. In the below example, we find a 49.3% rate of any adverse event for Placebo treatment against 60.7% and 63.4% for Tanezumab and NSAID/Tanezumab combination therapy, respectively

(NESTED) NOWLEDGE					Our 1	feam Our Vision	Enterprise 🔼	itoLit 🛛 Karl 🕦
(Synthesis Home 4)		Quantitative Synthesis: 0	steoarthritis: Tanez	umab				0
		Surrary Ditt	butice NVA				FaedE	Heds Random Effects
	Outcom	w		Outcome			Outcome	
Intervention	Abnormal Peripheral Sensations		Serious Adver	ne Events 🛛 🤇	(Any Advers	Events () • (
	Categori	ical	(n/N)	16	[0]	(n/N)	56	[ci]
♥Interventions	66 334	Paraethosia 800	608/12208	4.3%	[3.7%, 5.7%]	7368/12208	59.2%	[56.3%, 62.7%]
Tanezamab	Pero Hyporchesa El 205	Pacarchesa 380	376/7865	4.2%	[3.5%, 5.1%]	4858/7865	60.7%	[57.3%, 64.9%]
Placebo	Heppenfresia 15	Faracetheola 25	34/1659	2.4%	[1296, 3.396]	803/1659	49.3%	[44.8%, 53.8%]
♥Cembination Therapy	2 Hepoenfrenia 4 13	Paraeethesia 194	148/1530	2.0%	[7.9%, 71.7%]	1006/1530	63.4%	[53,1%, 72,6%]
♥NSAID and Tanezumab	A 13	Paraetheia 194	148/1530	2.0%	[7.9%, 71.7%]	1006/1530	63.4%	[\$337%, 72.6%]
VS mg + NSAD	1 Hyperthese 2 M	Parandresa 48	62,9696	3.0%	[6.6%, 12.2%]	463/686	65.5%	[\$0.2%, 78.2%]
Balanescu et al.	Peripheral neuropaths 2	Procesticaio 1	8/150	5.3%	[2.7%, 10.3%]	73/190	487%	[40.8%, 56.6%]
Schwitzer et al.	Hippenthesia 16	Paraetheia	280280	10.0%	[7.0%, 14.7%]	205/380	73.2%	[67.2%, 38.2%]
Schritzer et al.	Hyperdileox 19	Pasardheila	26/256	10.2%	[7.2%, 14.5%]	185,0356	72.3%	[68.5%, 77.4%]
10 mg + NSAID	P Hyperscherke	Reventional CO	74/687	10.9%	[7.996, 94.5W]	672/687	65.8%	[51.96, 79.4%]
1-2.5 mg + NSND	Honotholi	Paracethosia	12/157	7.6%	[4,4%,13.0%]	70/67	45.2%	[37,6%, 53,7%]
Disycodone	Hypsethesis 2	Paraethesia	4/158	2.5%	[10%, 6.5%]	100/158	63.3%b	[55.5%, 70.4%]
D-NSAD	Hyper-Checke 10	Paravetheria 15	46/996	4.0%	[1.5%, 6.1%]	63/996	60.3%	[57.3%, 63.3%]

The NMA tab computes a Network Meta-Analysis, which estimates effect sizes between pairwise comparisons of interventions on an outcome. The NMA comes with a network diagram (showing how commonly interventions were compared with one another), an effect size matrix, and forest plots (accessed by clicking on a cell in the effects matrix). Use the intervention expansion menu on the right of the page to refine interventions analyzed.



Closing Remarks

You've now seen how a review may be completed & shared with the Nested Knowledge platform. We encourage you to head back to AutoLit and explore the variety of configuration options, and evergrowing feature set we didn't get to cover here. If you're feeling ambitious, start your own Nest from scratch!

Use this documentation to guide you through more complex topics, and as always, please reach out to our support team via email and make requests on Nolt.

From: https://wiki.nested-knowledge.com/ - Nested Knowledge Permanent link: https://wiki.nested-knowledge.com/doku.php?id=wiki:start:demo:osteoarthritis Last update: 2023/06/27 21:52